Opis działalności
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Zarząd & Rada nadzorcza
| CEO |
| Naoki Okamura |
| Zarząd |
| Atsushi Kitamura, Katsuyoshi Sugita, Yoshitsugu Shitaka, Tadaaki Taniguchi, Hideki Shima, Claus Zieler, Adam Pearson, Catherine Levitt |
| Rada nadzorcza |
| Kenji Yasukawa, Naoki Okamura, Katsuyoshi Sugita, Takashi Tanaka, Eriko Sakurai, Masahiro Miyazaki, Yoichi Ohno, Toru Yoshimitsu, Raita Takahashi, Mika Nakayama, Rie Akiyama |
Dane firmy
| Nazwa: |
Astellas Pharma Inc. |
| Adres: |
2-5-1, Nihonbashi-Honcho,Chuo-Ku, Tokyo 103-8411 |
| Telefon: |
+81-3-3244-3000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.astellas.com/en/ |
| Przemysł: |
Służba zdrowia |
| Sektor: |
Przemysł Farmaceutyczny |
| Podsektor: |
- |
| Koniec roku finansowego: |
31.03 |
| Free float: |
- |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
- |
| Telefon: |
+81-3-3244-3202 |
| Fax: |
- |
| E-mail: |
-
|
